ABOUT DATAMONITOR HEALTHCARE
- About the Womens Health pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Objective of the analysis
- Datamonitor insight into the osteoporosis and HRT market
CHAPTER 2 MARKET DEFINITION AND OVERVIEW
- Market definition for this report
- Current market situation
- Strategic scope and focus
- Epidemiology of osteoporosis
- Methodological difficulties in assessing prevalence
- Prevalence of osteoporosis and osteopenia in postmenopausal women
- Overview of the prevalence of osteoporosis and osteopenia in
postmenopausal women
- US
- Japan
- France
- Germany
- Italy
- Spain
- UK
- Segmentation of osteoporosis
- Prevalence of osteoporosis and osteopenia in men
- Introduction
- Overview of the prevalence of osteoporosis/osteopenia in men
- US
- Japan
- France
- Germany
- Spain
- UK
CHAPTER 3 COUNTRY MARKET ASSESSMENTS
- Current and future opportunities and threats in the osteoporosis and HRT
market
- Global opportunities and threats
- US: opportunities and threats
- Japan: opportunities and threats
- France: opportunities and threats
- Italy: opportunities and threats
- UK: opportunities and threats
CHAPTER 4 FORECAST ANALYSIS
- Assumptions and events
- Bisphosphonates
- Fosamax
- Actonel
- Pipeline bisphosphonates
- SERMs
- Calcitonins
- Miacalcin
- Pipeline calcitonins
- Parathyroid hormone derivatives
- Forteo
- Pipeline PTH therapy
- Hormone therapy
- Limitations of data
- Forecasts
CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES
- Introduction
- Case studies
- Wyeth HRT portfolio strategy - preserving the Premarin brand and
gambling on new molecules
- Premarin/Prempro
- Bazedoxifene and trimegestone
- NPS pre-launch strategy for Preos - piggybacking Kineret detailing
activity
- Chugai cornering the Japanese market
- Mercks Fosamax launch activity
- Heavy Phase IV activity among top three drugs
- Combination trials with Forteo, Evista and Fosamax
- Impact of the WHI on non-hormonal osteoporosis drugs
APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS
- Bisphosphonates market data
- SERMs market data
- Calcitonins market data
- PTH market data
APPENDIX B
- Bibliography
- Epidemiology
- Clinical trial data
- Report methodology
- About Datamonitor
- About Datamonitor Healthcare
- About the Disease analysis team
- Key therapy team members
- Name, Director Disease
- Disclaimer
- List of Tables
- Table 1: Key players in the osteoporosis and HRT market
- Table 2: WHO classification of osteoporotic bone loss
- Table 3: Epidemiology overview of osteoporosis
- Table 4: Prevalence of osteopenia and osteoporosis in postmenopausal
women across the seven major markets, 2003
- Table 5: Prevalence of osteopenia and osteoporosis in men over 50 in
the seven major markets, 2003
- Table 6: Fosamax: key facts
- Table 7: Actonel: key brand facts
- Table 8: Evista: key facts
- Table 9: Miacalcin: key facts
- Table 10: Forteo: key facts
- List of Figures
- Figure 1: Prevalence of osteopenia and osteoporosis in postmenopausal
women across the seven major markets, 2003
- Figure 2: Prevalence of osteopenia and osteoporosis in men over 50 in
the seven major markets, 2003
- Figure 3: Impact of Fosamax genericization by volume
- Figure 4: Critical success factors for treating physicians to
prescribe novel bisphosphonates over currently marketed products
- Figure 5: US five-year sales trend of Premarin and Prempro
- Figure 6: US DTC advertising spend for Premarin and Prempro ($000s),
1998(2003
- Figure 7: Premarin/Prempro online homepage
- Figure 8: Forecast of Evista US sales with approval in breast cancer
and CVD indications, $000s, 2003(14
- Figure 9: Summary of Phase IV trial strategies for key marketed
osteoporosis brands
- Figure 10: Impact of WHI on sales of key osteoporosis brands from 2001
to 2003, $bn
- Figure 11: Change in share and value of key non-hormonal osteoporosis
brands before and after the 2002 release of WHI study data
View Cart
